Back to Directory

Maggie Albano

Email

malbano@fhi360.org

Phone

202-464-3753

Institution

FHI 360

Address

IMPAACT Operations Center
FHI 360
359 Blackwell Street
Suite 200
Durham, NC 27701
USA

Request an Update

Affiliated Studies

IMPAACT 2046: UPLIFT Study

DAIDS Number

Research Area

Brain and Mental Health

Study Status

IMPAACT 2038: Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of Recombinant, Live-Attenuated, Bovine/Human, Parainfluenza Virus Type 3 (B/HPIV3) Vector Vaccines B/HPIV3/RSV/PreF, B/HPIV3/RSV/PreF/TM, or Placebo, Delivered via Nasal Sprayer to HPIV3-Seronegative Children 6 to 24 Months of Age

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

DAIDS Number

Research Area

Study Status

Closed to Accrual

IMPAACT 2016: Evaluating a Group-Based Intervention to Improve Mental Health and ART Adherence Among Youth Living with HIV in Low Resource Settings

DAIDS Number

Research Area

Brain and Mental Health

Study Status

Closed to Accrual

IMPAACT 2021: Randomized Phase I/II Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV delta NS2/ delta 1313/I1314L, RSV 6120/ delta NS2/1030s, RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Children 6 to 24 Months of Age

DAIDS Number

Research Area

Cure and Immunotherapy

Study Status

Participants Off Study and Primary Analysis Completed